Linagliptin

Details

Files

Generic Name:

Linagliptin

Project Status:

Complete

Therapeutic Area:

Diabetes mellitus, type 2

Manufacturer:

Boehringer Ingelheim Canada

Call for patient/clinician input open:

August 9, 2011

Brand Name:

Trajenta

Project Line:

Reimbursement Review

Project Number:

SR0244-000

Call for patient/clinician input closed:

September 14, 2011

NOC Status at Filing:

Post NOC

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Diabetes mellitus, Type 2

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

February 15, 2012

Files

Recommendation and Reasons: Updated View PDF

Submission Status Report View PDF

Recommendation and Reasons: Original View PDF

Last Updated : March 22, 2024